Dr Helen Coley

Biography

Qualifications

BSc University of Surrey, Biochemistry with Toxicology

FIMLS (Fellow of the Institute of Medical Laboratory Sciences) University of Portsmouth, (Clinical Biochemistry)

PhD University of Cambridge, Clinical Oncology and Radiotherapeutics Unit (CORU), Laboratory of Molecular Biology, Hills Road, Cambridge.

MILT Member of the Institute of Learning and Teaching

Research Interests

Research Background and Interests

The molecular biology of cancer 

Disease sites of interest: breast, brain, ovarian and prostate

Anticancer drug resistance

New developmental anticancer agents: 

Cytotoxic agents: 

Taxane and epothilone compounds

Nanotechnology

Research Collaborations

Collaborations within the University of Surrey:

Ion Beam Centre: Prof Karen Kirkby

Collaborations with the Pharmaceutical Industry:

Astra Zeneca: small molecule receptor tyrosine kinase inhibitors (Iressa, gefitinib)

Bristol Myers Squibb: epothilone B analogue (Ixabepilone)

Cyclacel: cell cycle inhibitory agents (CYC202; seliciclib)

Pharmacia: COX-2 inhibitors (Celebrex; celecoxib)

Novartis

GlaxoSmithKline: 

Pfizer: MET (hepatocyte growth factor receptor) small molecule inhibitor (PF2341066)

Teaching

BSc Level 3 Cancer Pathogenesis and Therapeutics (module organiser)

MSc Toxicology (Mutagenesis and Carcinogenesis)